Strata Critical Medical (SRTA) Research & Development (2020 - 2025)

Strata Critical Medical (SRTA) has reported Research & Development for 6 consecutive years, with $453000.0 the latest figure, recorded in Q3 2025.

• In Q3 2025, Research & Development rose 44.27% year-over-year to $453000.0; the TTM figure through Sep 2025 stood at $10.4 million (up 58105.56% YoY), while the FY2024 annual figure was $8.0 million, up 71.82% from the prior year.
• Research & Development slipped to $453000.0 in Q3 2025 per SRTA's latest filing, from $1.6 million in the prior quarter.
• Across five years, Research & Development topped out at $6.9 million in Q4 2024 and bottomed at -$3.4 million in Q4 2023.
• Historically, Research & Development has averaged $1.4 million across 5 years, with a median of $1.4 million in 2023.
• On a YoY basis, Research & Development climbed as much as 303.62% in 2024 and fell as far as 88.31% in 2024.
• Strata Critical Medical's Research & Development stood at $1.5 million in 2021, then surged by 30.29% to $1.9 million in 2022, then slumped by 279.12% to -$3.4 million in 2023, then jumped by 303.62% to $6.9 million in 2024, then sank by 93.45% to $453000.0 in 2025.
• Business Quant data shows SRTA's Research & Development at $453000.0 in Q3 2025, $1.6 million in Q2 2025, and $1.4 million in Q1 2025.